TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07259213: A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting

Sponsor: Radiopharm Theranostics, Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 73 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07259213 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07259213 Rescue Dossier →